Patient Opportunity Equity Strategy Q3 2025 Portfolio Recap [Seeking Alpha]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
The largest quarterly contributor to performance was Precigen (PGEN $3.19), which contributed more than 500bps. We started a small position in UnitedHealth (UNH $367.69) in the second quarter and added aggressively during its third quarter sell-off. tadamichi/iStock via Getty Images By Samantha McLemore Patient Opportunity Equity Strategy performed well in the third quarter, gaining 14.1% versus our benchmark, the S&P 500's 8.1% return. This brings our year-to-date gains to 18.9% vs. the S&P 500's 14.8%. Since I took over sole management of Opportunity at the end of 2022, it's gained 31.5% per year versus the S&P 500's 24.1% annual gain. The largest quarterly contributor to performance was Precigen ( PGEN $3.19), which contributed more than 500bps. We led a private investment in December 2024 through a preferred investment with warrants. We've known the company for over a decade and saw a lucrative opportunity to solve the company's capital needs in advance of an August FDA d
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]Seeking Alpha
- Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]Seeking Alpha
- Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]Yahoo! Finance
- Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]Yahoo! Finance
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- PGEN's page on the SEC website